News & Events – Page 2 – Sumitovant

Select Company

May 09, 2022Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
May 06, 2022Altavant Sciences Presents Data Showing Potential for Combination of Rodatristat Ethyl and Ambrisentan in Model of Pulmonary Arterial Hypertension
May 02, 2022Altavant Sciences Presented Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
April 29, 2022Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
April 25, 2022Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
April 22, 2022Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
April 19, 2022Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® (Vibegron) 75mg in Dry and Wet Overactive Bladder Populations
April 13, 2022Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting
April 04, 2022Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer
March 25, 2022Sumitovant Biopharma and its Portfolio of Companies Announce Milestone Highlights from the Third Quarter of FY2021
« Previous 1 2 3 4 … 22 Next »